These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32742453)

  • 21. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of Lung Stereotactic Ablative Radiotherapy at a Regional Cancer Centre.
    Clayton R; Liu HW; Khan R; Udowicz M; Bayliss Y; Krobutschek K; Herring C; Lau H
    J Med Imaging Radiat Sci; 2012 Dec; 43(4):245-252. PubMed ID: 31052011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?
    Fernández C; Navarro-Martin A; Bobo A; Cabrera-Rodriguez J; Calvo P; Chicas-Sett R; Luna J; Rodríguez de Dios N; Couñago F
    World J Clin Oncol; 2022 Feb; 13(2):101-115. PubMed ID: 35316929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions.
    Zayed S; Louie AV; Breadner DA; Palma DA; Correa RJM
    Ther Adv Med Oncol; 2023; 15():17588359231183668. PubMed ID: 37435562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea.
    Song S; Chang JH; Kim HJ; Kim YS; Kim JH; Ahn YC; Kim JS; Song SY; Moon SH; Cho MJ; Youn SM
    Cancer Res Treat; 2017 Jul; 49(3):688-694. PubMed ID: 27809459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review.
    Glicksman RM; Tjong MC; Neves-Junior WFP; Spratt DE; Chua KLM; Mansouri A; Chua MLK; Berlin A; Winter JD; Dahele M; Slotman BJ; Bilsky M; Shultz DB; Maldaun M; Szerlip N; Lo SS; Yamada Y; Vera-Badillo FE; Marta GN; Moraes FY
    JAMA Oncol; 2020 Apr; 6(4):567-577. PubMed ID: 31895403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
    Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
    [No Abstract]   [Full Text] [Related]  

  • 29. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
    Bilal H; Mahmood S; Rajashanker B; Shah R
    Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
    Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
    Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
    Shibamoto Y; Miyakawa A; Otsuka S; Iwata H
    J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i76-i82. PubMed ID: 27006380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal tumour control for early-stage non-small-cell lung cancer: A radiobiological modelling perspective.
    Alaswad M; Kleefeld C; Foley M
    Phys Med; 2019 Oct; 66():55-65. PubMed ID: 31561206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
    Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
    Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
    Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
    J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization.
    Lee HL; Tsai JT; Chen CY; Lin YC; Ho CB; Ting LL; Kuo CC; Lai IC; Lin CY; Tang JH; Huang YM; Kao WY; Cheng SW; Shen CN; Chen SW; Chiou JF
    Ther Adv Med Oncol; 2019; 11():1758835919889002. PubMed ID: 31839809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.
    Prasanna A; Ahmed MM; Mohiuddin M; Coleman CN
    J Thorac Dis; 2014 Apr; 6(4):287-302. PubMed ID: 24688774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
    Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.
    Palma DA; Haasbeek CJ; Rodrigues GB; Dahele M; Lock M; Yaremko B; Olson R; Liu M; Panarotto J; Griffioen GH; Gaede S; Slotman B; Senan S
    BMC Cancer; 2012 Jul; 12():305. PubMed ID: 22823994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.